Based on our recent studies [7] and the results shown herein (Figs. 1, 2, 4, 7 and 8), the activation status of these three interconnected pathways, i.e., Wnt/non-canonical NF-κB/NRF2, supports the downregulation of DDX5 in advanced HCC, emphasizing the therapeutic potential of targeting these interconnected pathways. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.